FORT WORTH, Texas, Oct. 29 /PRNewswire-FirstCall/ -- Wound Management
Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that the company
is currently negotiating with several organizations looking to license WMT's
proprietary activated collagen products for wound care management outside the
United States.
"Wound Management Technologies has been working with various medical
professionals to demonstrate how and why WMT's collagen products significantly
outperform other collagen products on the market today. The positive results
we have received from these demonstrations has generated both national and
international interest and has provided us with the opportunity to bring in
wound care organizations in different regions of the world as business
partners," said Scott Haire, the company's Chief Executive Officer.
From a worldwide perspective, wound care is a $20 billion plus health care
expenditure, explains the company's Chief Operations Officer, Bobby Stout.
Stout added "We continue to examine existing and future partner relationships
as a means to be able to achieve and maximize our revenues. By releasing
additional evidence based studies and performing more clinical research, we
believe we will continue to demonstrate why WMT's activated collagen products
produce the best results on diabetic wounds, as well as other patients
requiring wound management." CellerateRx(R), WMT's current activated collagen
product, is FDA cleared for use on all wound types, except for 3rd degree
burns and is effective in all wound phases.
Evidence of the efficacy of WMT's activated collagen was recently
presented at the 9th annual New Cardiovascular Horizons (NCVH) and Management
of the Diabetic Foot and Wound Healing conference, held September 10-13, 2008
in New Orleans. NCVH is one of the largest international multi-disciplinary
conferences. The presentation was on Friday, September 12, 2008 during the
session 2nd Annual New Therapeutic Wound Care Technology Summit: Emerging Use
of Topical "Biologics" in Limb Salvage--Role of "Activated Collagen" in
Multimodality Treatment. The entire presentation can be seen on the WMT's web
site or using these links listed here:
Please click here to view Presentation:
http://www.newcvhorizons.com/uploads/gary%20rothenberg.pdf
For ALL presentations of the NCVH 2008 conference, click here:
http://www.newcvhorizons.com/site223.php
Wound Management Technologies, Inc., also announced today that its
subsidiary, Wound Care Innovations, LLC, will exhibit at the 23rd Annual
Clinical Symposium on Advances in Skin and Wound Care: The Conference for
Prevention and Healing at the Rio All Suite Hotel in Las Vegas, Nevada. The
Symposium is designed to enable the attendee to apply basic to advanced
concepts in the science of wound healing or in preventing and managing wounds.
Presented will be cutting-edge treatments, emerging technologies, and research
breakthroughs which will assist clinicians in identifying credible, balanced,
and relevant clinical practice issues.
"This conference is an excellent opportunity for us to present our
advanced wound care product, CellerateRx(R)" states Cathy Bradshaw, President
of Wound Care Innovations. "We are especially excited about this conference
as there were case reports using CellerateRx(R) in the August issue of the
wound care journal, Advances in Skin & Wound. The Symposium allows us to
target key wound care specialists from all around the United States and
international attendees as well."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in Fort Worth, Texas, markets and distributes wound
care products to the healthcare market under patented technology licensed to
the Company. The Company is positioned and seeks to be a leading provider of
wound care products. For more information on the Company please visit the
Company's Website at: www.Celleraterx.com
"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.
For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
President Secretary
954-315-9242 817-820-7080
SOURCE Wound Management Technologies, Inc.
